Moreover, targeting IGF2BP3 either through small molecule inhibitors or monoclonal antibodies represents a promising approach to resensitize bladder cancer cells to cisplatin, potentially improving treatment outcomes. The gene discussed is IGF2BP3; the disease is urinary bladder carcinoma.